Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Gilead Files Trodelvy for Triple-Negative Breast Cancer in Japan
January 31, 2024
- US FDA Approves Additional CIDP Use for Takeda’s Gammagard Liquid
January 31, 2024
- Takeda’s Hyqvia Nabs European Approval for CIDP Maintenance Therapy
January 31, 2024
- Susmed Drops Reimbursement Request for Insomnia App
January 30, 2024
- Enhertu Gets FDA’s Priority Review for Pan-Tumor Indication: Daiichi Sankyo
January 30, 2024
- Astellas/Pfizer Seeks 1st Line Bladder Cancer Use for Padcev/Keytruda in EU
January 30, 2024
- Eisai Resubmits Ultra-High Dose Mecobalamin in Japan for ALS
January 29, 2024
- Mitsubishi Tanabe Newly Pledges 100 Billion Yen for GHIT Fund
January 29, 2024
- Tecentriq/Cabometyx Cuts Risk of Disease Progression or Death by 35% in CRPC
January 29, 2024
- Towa Begins Priority Supply of 23 APIs, Mostly under Shipment Curbs, to Quake-Hit Area
January 26, 2024
- Shionogi Partners with Niremia Collective to Fund Well-Being Tech Startups
January 26, 2024
- BlueRock In-Licenses Fujifilm’s iPSC Therapy for Ocular Disease
January 25, 2024
- Kyowa Kirin Closes Acquisition of UK Gene Therapy Player Orchard
January 25, 2024
- Takeda’s Cuvitru Now Available in Japan as Its First SC Immunoglobulin
January 25, 2024
- Ono Revs Up to Boost Global Presence, Launches New HR Scheme
January 24, 2024
- Astellas to Discontinue IBS Med Colonel in Product Consolidation
January 24, 2024
- Astellas to Transfer Distribution Rights for Antibacterial Geninax to Taisho
January 24, 2024
- Mitsubishi Tanabe, Pfizer to Copromote 5-in-1 Vaccine Gobik
January 24, 2024
- Prefilled Syringe Versions of Hizentra Approved in Japan: CSL
January 23, 2024
- Nippon Shinyaku Snags EU Orphan Tag for EGPA Drug
January 23, 2024
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…